MYCN and neoplasm: Serum MYCN amplification (sensitivity 86%, specificity 95% compared with tissue analysis) was associated with OS. It may help selecttreatment prior to tumor biopsy, particularly for patients < 18 months(risk assessment and treatment depend on MYCN amplification status).